CIBC Asset Management Inc Acquires 1,149 Shares of Hologic, Inc. (HOLX)
CIBC Asset Management Inc raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,285 shares of the medical equipment provider’s stock after buying an additional 1,149 shares during the period. CIBC Asset Management Inc’s holdings in Hologic were worth $1,692,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of HOLX. TrimTabs Asset Management LLC increased its position in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 1,408 shares during the period. Beck Mack & Oliver LLC acquired a new position in Hologic during the second quarter valued at $209,000. Notis McConarty Edward acquired a new position in Hologic during the second quarter valued at $213,000. Advisor Partners LLC acquired a new position in Hologic during the first quarter valued at $201,000. Finally, Miles Capital Inc. acquired a new position in Hologic during the first quarter valued at $206,000. Hedge funds and other institutional investors own 94.46% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 38.33 on Thursday. The firm’s 50 day moving average is $44.21 and its 200 day moving average is $42.94. The firm has a market capitalization of $10.75 billion, a PE ratio of 14.28 and a beta of 0.90. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.51 EPS. Analysts anticipate that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
Several equities analysts have weighed in on the stock. Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 target price (down from $50.00) on shares of Hologic in a report on Wednesday. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday. Deutsche Bank AG dropped their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Barclays PLC restated an “equal weight” rating and set a $51.00 target price (down from $53.00) on shares of Hologic in a report on Wednesday. Finally, Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a report on Sunday, May 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. Hologic currently has an average rating of “Buy” and a consensus price target of $48.64.
In related news, Director Lawrence M. Levy sold 9,076 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $42.80, for a total value of $388,452.80. Following the completion of the sale, the director now owns 43,165 shares of the company’s stock, valued at approximately $1,847,462. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Elaine Ullian sold 8,938 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $43.99, for a total value of $393,182.62. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,047,401.90. The disclosure for this sale can be found here. In the last three months, insiders sold 60,627 shares of company stock valued at $2,632,911. 0.79% of the stock is currently owned by company insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.